KRAS and non-small cell lung carcinoma: For example, activation of the IGFR1R has been shown to be essential in KRAS-mutant-mediated PI3K activation in Non-Small Cell Lung Cancer (NSCLC) and colorectal cancer (CRC), whereas EGFR appears to have strong importance in KRAS-WT-mediated PI3K activation in NSCLC models (Molina-Arcas et al., 2013; Ebi et al., 2011).